Holen Sie sich die Stockscreener-App
0.344
5.74%
-0.0209
Handel nachbörslich:
.34
-0.004
-1.16%
Aptose Biosciences Inc Aktie (APTO) Neueste Nachrichten
ARMISTICE CAPITAL, LLC Increases Stake in Aptose Biosciences Inc - GuruFocus.com
Aptose Biosciences Inc. (APTO) Quarterly 10-Q Report - Quartzy
Aptose Biosciences Reports Q3 2024 Financial Highlights - TipRanks
Aptose Reports Results for the Third Quarter 2024 - GlobeNewswire
Aptose Biosciences Cuts Q3 Losses, Secures $10M Loan Amid Nasdaq Challenges | APTO Stock News - StockTitan
Aptose Biosciences faces delisting from NASDAQ - Investing.com India
Aptose Biosciences faces delisting from NASDAQ By Investing.com - Investing.com South Africa
Analysts’ New Coverage for September 18th (AINC, AIRI, APTO, ARM, AVGO, BGNE, CAN, CARA, CHH, CLLS) - Defense World
Aptose Biosciences secures shareholder nod for warrant issuance - Investing.com
Aptose Biosciences stock hits 52-week low at $0.34 - Investing.com
Aptose Biosciences Shareholders Endorse Key Resolutions - TipRanks
Aptose Announces Results from Special Meeting of Shareholders - GlobeNewswire
A significant driver of top-line growth: Aptose Biosciences Inc (APTO) - SETE News
Aptose Biosciences Inc Inc. (APTO) Price Performance: A Technical Analysis Perspective - The InvestChronicle
APTO’s earnings forecast for the current quarter - US Post News
Daily Market Movement: Aptose Biosciences Inc (APTO) Sees a 2.19 Increase, Closing at 0.41 - The Dwinnex
Hello Group, Zscaler And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Aptose Biosciences secures funds for AML treatment development - Pharmaceutical Technology
Aptose Biosciences (NASDAQ:APTO) Receives New Coverage from Analysts at StockNews.com - Defense World
Aptose secures $10 million loan for leukemia drug development - Investing.com India
APTOAptose Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
Aptose Biosciences Secures Convertible $10M Loan from Hanmi - TipRanks
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib - Yahoo Finance
Aptose Receives $10 Million Through a Facility Agreement - GlobeNewswire
StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Aptose Biosciences stock hits 52-week low at $0.4 amid downturn - Investing.com
APTO’s Market Whiplash: -81.82% YTD Decline, -24.89% Plunge in 30 Days - The InvestChronicle
Market Resilience: Aptose Biosciences Inc (APTO) Finishes Weak at 0.46, Down -4.82 - The Dwinnex
Aptose Biosciences (NASDAQ:APTO) vs. ImmunityBio (NASDAQ:IBRX) Critical Review - Defense World
Aptose Biosciences: Bottom 25 Performing Stocks Year-To-Date On TSX (APS) - Barchart
Aptose Announces Adjournment of its Special Meeting of Shareholders - GlobeNewswire
Aptose Biosciences (NASDAQ:APTO) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS - Defense World
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q2 2024 - MSN
Aptose Biosciences: Q2 Earnings Snapshot - Houston Chronicle
Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com - Defense World
Aptose Reports Results for the Second Quarter 2024 - GlobeNewswire
Aptose Biosciences Inc (APS-T) QuotePress Release - The Globe and Mail
Aptose Biosciences stock hits 52-week low at $0.55 amid downturn - Investing.com Australia
Aptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.com - Defense World
Caspase 3 Market – 37% of Growth to Originate from APAC -Aptose Biosciences Inc, BeyondSpring Pharmaceuticals Inc, Conat – Moose Gazette - Moose Gazette
Aptose Biosciences Inc. (NASDAQ:APTO) Receives Average Recommendation of “Buy” from Brokerages - Defense World
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):